Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

@article{Curigliano2012CardiovascularTI,
  title={Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.},
  author={Giuseppe Curigliano and Daniela Maria Cardinale and T. Suter and George A. Plataniotis and Evandro de Azambuja and M. T. Sandri and Carmen Criscitiello and Aron Goldhirsch and C M Cipolla and Fausto Roila},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2012},
  volume={23 Suppl 7},
  pages={
          vii155-66
        }
}
Cardiovascular (CV) toxicity is a potential short- or long-term complication of various anticancer therapies. Some drugs, such as anthracyclines or other biological agents, have been implicated in causing potentially irreversible clinically important cardiac dysfunction. Although targeted therapies are considered less toxic and better tolerated by patients compared with classic chemotherapy agents, rare but serious complications have been described, and longer follow-up is needed to determine… Expand

Paper Mentions

Observational Clinical Trial
Anthracyclines treat up to 60% of childhood malignancies with remarkable improvements survival rates. Unfortunately anthracyclines are associated with an increased cardiomyopathy… Expand
ConditionsAnthracycline Induced Cardiotoxicity
Interventional Clinical Trial
Tomographic radionuclide angiography (or blood pool) is a reproducible method to evaluate left ventricular ejection fraction that is needed during oncological treatments or to… Expand
ConditionsCardiac Function
InterventionOther
Cardiovascular Toxicity from Chemotherapy and Anticancer Treatment
TLDR
Assessment of the prevalence, type, and severity of cardiac toxicity caused by various cancer treatments is a breakthrough topic for patient management and more research is needed to assess and manage the cardiovascular safety of patients treated with anticancer agents. Expand
Cardiac Complications of Chemotherapy: Role of Prevention
TLDR
The future of the prevention of cardiac toxicity should include the study of the exact mechanism of toxicity of each cardiotoxic drug and the genetic individual susceptibility of each patient to correct risk stratification when planning the initial therapy. Expand
The concomitant management of cancer therapy and cardiac therapy.
TLDR
Active collaboration of physicians with laboratory scientists is much needed for improving management of cardiovascular sequelae of antitumor therapy, and patient-tailored pharmacologic correction of comorbidities is important for both primary and secondary prevention. Expand
Chemotherapy-induced cardiotoxicity: detection, prevention, and management.
TLDR
The common systemic drugs with cardiotoxic potential and the monitoring and diagnostic tools, including the role of biomarkers for early detection, are reviewed and the use of cardioprotectant agents as pharmacological interventions in prophylactic and treatment settings is reviewed. Expand
Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.
TLDR
A review discussing cardiotoxic effects of drugs and guidelines for management of the toxicities to assist the medical field in general managing patients with cancer is presented. Expand
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.
TLDR
Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment, and guidance regarding prevention, screening, monitoring and treatment of CV toxicity is provided. Expand
Cardiooncology—dealing with modern drug treatment, long-term complications, and cancer survivorship
TLDR
This review focusses on acute and long-term cardiotoxic side effects of classical cytotoxic and selected modern drug treatments such as immune checkpoint inhibitors and discusses strategies for the diagnosis of treatment-related adverse cardiovascular effects in cancer patients. Expand
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
TLDR
This work advocates administering dexrazoxane during cancer treatment to limit the cardiotoxic effects of anthracycline chemotherapy, and suggests the routine use of neurohormonal antagonists for cardioprotection is not currently justified. Expand
Cancer Cardiotoxicity and Cardiac Biomarkers
TLDR
A new appealing approach has been proposed: it is based on the evaluation of circulating troponin and/or natriuretic peptides, which can detect minimal cardiac damage well before the onset of cardiac dysfunction, allowing for a personalized follow-up and cardiological preventive treatment. Expand
Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease.
TLDR
This review considers the cardiotoxic effects of specific cancer therapies and discusses novel diagnostic and therapeutic approaches as a reference for optimizing the care of cancer patients receiving novel cancer therapies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
Cancer drugs and the heart: importance and management.
TLDR
Concepts for timely diagnosis, intervention, and surveillance of cancer patients undergoing treatment, and approaches to clinical uncertainties are discussed to prevent long-term damage. Expand
Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
TLDR
Following the occurrence of asymptomatic LVEF reduction or CHF and appropriate medical intervention, reintroduction of trastuzumab may be considered in patients following resolution of normal cardiac function, or in those for whom the benefit of antitumor therapy outweighs the risk for CHF. Expand
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
TLDR
The screening of patients, optimization of therapeutic schemes, monitoring of cardiovascular function during treatment, and the management of cardiovascular side effects are likely to become increasingly important in cancer patients. Expand
Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage
TLDR
Evidence suggests that high-risk patients will benefit from prophylactic treatment with neurohormonal blockade by angiotensin-converting enzyme inhibitors and beta-adrenergic receptor blockers and newer imaging modalities and cardiac biomarkers may be useful in improving early detection of cardiac injury and dysfunction. Expand
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
TLDR
This review examines the cardiac toxicity of adjuvant therapy, monitoring for early changes and existing guidelines for monitoring cardiac function in patients with breast cancer. Expand
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
TLDR
The observations indicate that cardiac damage from TKI treatment is a largely underestimated phenomenon but is manageable if patients have careful cardiovascular monitoring and cardiac treatment at the first signs of myocardial damage. Expand
Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
TLDR
In high-risk, HDC-treated patients, defined by an increased troponin I value, early treatment with enalapril seems to prevent the development of late cardiotoxicity. Expand
Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil.
TLDR
A retrospective analysis was performed on two randomized phase III studies comparing the two regimens as first-line therapy for patients with metastatic colorectal cancer and taxane-pretreated metastatic breast cancer, revealing a similar low incidence of capecitabine-related cardiotoxic events in patients with MCRC and MBC. Expand
Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development.
TLDR
A pragmatic and thoughtful strategy to assess the QT-liability of a cytotoxic agent in early phase I-II studies without compromising the objectives of these studies or patient access to potentially beneficial novel agents is proposed. Expand
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
TLDR
Recommendations are devised that promote proactive pharmacological management of cardiac function in trastuzumab-treated patients, and that apply to all patients who are likely to receive standard cytotoxic chemotherapy. Expand
...
1
2
3
4
5
...